Literature DB >> 35305364

Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer.

Peter F G Foulser1, Nishanthi Senthivel2, Kate Downey2, Paul E Hart2, Sophie E McGrath2.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a complex neurological disorder with multiple clinical manifestations including headaches, seizures, and altered mental status. It is associated with many conditions including malignancy and medications including chemotherapy and immunotherapy. We report the case of a 56-year old female with a history of advanced triple negative breast cancer treated with atezolizumab (a PD-L1 inhibitor), paclitaxel and ipatasertib (investigational AKT inhibitor), who developed hypertension, confusion, and imaging findings consistent with PRES.
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Atezolizumab; Breast cancer; Posterior reversible encephalopathy

Mesh:

Substances:

Year:  2022        PMID: 35305364     DOI: 10.1016/j.ctarc.2022.100548

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  1 in total

1.  Posterior Reversible Encephalopathy Syndrome Onset Within 24 Hours Following Moderna mRNA Booster COVID-19 Vaccination: Vaccine Adverse Event Vs. Hypertension?

Authors:  Jocelyn McCullough; Manal Ahmad; Idy Tam; Reid Portnoy; Joseph Ng; Kuschner Zachary; Alan Kaell
Journal:  Cureus       Date:  2022-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.